Big Gain For Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX:NASDAQ) shot up at $6.28, representing a gain of 54.7%. The stock appeared on our News Catalysts scanner on Thu 05 Dec 19 at 08:31 AM in the 'RECOMMENDATION' category. From Fri 15 Nov 19, the stock recorded 50.00% Up Days and 66.67% Green Days
About Neoleukin Therapeutics, Inc. (NLTX:NASDAQ)
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. It generates immunotherapies using de novo protein design technology. The firm uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises of NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Top 10 Gainers:
- Synthorx, Inc. (THOR:NASDAQ), 170.52%
- Forty Seven, Inc. (FTSV:NASDAQ), 110.73%
- ArQule, Inc. (ARQL:NASDAQ), 103.88%
- XBiotech Inc. (XBIT:NASDAQ), 75.36%
- Neoleukin Therapeutics, Inc. (NLTX:NASDAQ), 54.68%
- Fate Therapeutics, Inc. (FATE:NASDAQ), 41.33%
- Aptose Biosciences Inc. (APTO:NASDAQ), 38.28%
- LMP Automotive Holdings, Inc. (LMPX:NASDAQ), 37.91%
- Hebron Technology Co., Ltd. (HEBT:NASDAQ), 33.17%
- Shineco, Inc. (TYHT:NASDAQ), 32.77%